Cognitive performance and psychosocial functioning in patients with bipolar disorder, unaffected siblings, and healthy controls
- PMID: 27096411
- PMCID: PMC7111353
- DOI: 10.1590/1516-4446-2015-1868
Cognitive performance and psychosocial functioning in patients with bipolar disorder, unaffected siblings, and healthy controls
Abstract
Objective:: To assess cognitive performance and psychosocial functioning in patients with bipolar disorder (BD), in unaffected siblings, and in healthy controls.
Methods:: Subjects were patients with BD (n=36), unaffected siblings (n=35), and healthy controls (n=44). Psychosocial functioning was accessed using the Functioning Assessment Short Test (FAST). A sub-group of patients with BD (n=21), unaffected siblings (n=14), and healthy controls (n=22) also underwent a battery of neuropsychological tests: California Verbal Learning Test (CVLT), Stroop Color and Word Test, and Wisconsin Card Sorting Test (WCST). Clinical and sociodemographic characteristics were analyzed using one-way analysis of variance or the chi-square test; multivariate analysis of covariance was used to examine differences in neuropsychological variables.
Results:: Patients with BD showed higher FAST total scores (23.90±11.35) than healthy controls (5.86±5.47; p < 0.001) and siblings (12.60±11.83; p 0.001). Siblings and healthy controls also showed statistically significant differences in FAST total scores (p = 0.008). Patients performed worse than healthy controls on all CVLT sub-tests (p < 0.030) and in the number of correctly completed categories on WCST (p = 0.030). Siblings did not differ from healthy controls in cognitive tests.
Conclusion:: Unaffected siblings of patients with BD may show poorer functional performance compared to healthy controls. FAST scores may contribute to the development of markers of vulnerability and endophenotypic traits in at-risk populations.
Conflict of interest statement
MKS has received speaking fees Eli Lilly. FK has received grants/research support from AstraZeneca, Eli Lilly, Janssen-Cilag, and Servier; has been a member of the speakers’ board for AstraZeneca, Eli Lilly, Janssen, and Servier; and has served as a consultant for Servier. EV has served as consultant, advisor, and/or speaker for Almirall, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest Research, Geodon Richter, GlaxoSmithKline, Janssen-Cilag, Jazz, Lundbeck, Merck, Novartis, Organon, Otsuka, Pfizer, Sanofi-Aventis, Servier, Solvay, Schering-Plough, Takeda, United Biosource, and Wyeth. The other authors report no conflicts of interest.
References
-
- Antypa N, Serretti A. Family history of a mood disorder indicates a more severe bipolar disorder. J Affect Disord. 2014;156:178–86. - PubMed
-
- Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8–19. - PubMed
-
- Rosa AR, Magalhães PV, Czepeilewski L, Sulzbach MV, Goi PD, Vieta E, et al. Clinical staging in bipolar disorder: focus on cognition and functioning. J Clin Psychiatry. 2014;75:e450–6. - PubMed
-
- Gonzalez-Pinto AM, Dardennes R, de Zélicourt M, López P, Oliveros RG, Vieta E, et al. In-patient care costs of patients with bipolar I disorder: a comparison between two European centers. J Affect Disord. 2010;121:152–5. - PubMed
-
- Tohen M, Hennen J, Zarate CM, Jr, Baldessarini RJ, Strakowski SM, Stoll AL, et al. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry. 2000;157:220–8. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical